Introduction: Low and middle income countries (LMICs) bear more than 50% of the current
cervical cancer burden over the last decade with linkages to lack of HPV vaccination, high …

Background: Prophylactic human papilloma virus (HPV) vaccines represent a promising
option for cervical cancer (CC) prevention in countries where screening, diagnostics and …

Abstract The World Health Organization recommends establishing that human
papillomavirus vaccination is cost-effective before vaccine introduction. We searched …

Background Cervical cancer ranks fourth amongst the commonest malignancies worldwide
and the second most prevalent cancer afflicting women in low-to-middle income countries …

Prophylactic vaccines for human papillomavirus (HPV) are being introduced in many
countries for the prevention of cervical cancer, the second most important cause of cancer …

Introduction The World Health Organization (WHO) recommends that human papillomavirus
(HPV) vaccination programs are established to be cost-effective before implementation …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Fifteen years following the approval of the first human papillomavirus (HPV) vaccine,
cervical cancer continues to be a significant source of morbidity and mortality among women …

Background Cervical cancer is a major public health problem in Latin America. Cost-
effectiveness studies help stakeholders with decisions regarding human papillomavirus …

Introduction: The cervical cancer-related burden is an important problem in Southeast Asian
(SEA) countries. However, only 3 out of 11 countries implement the comprehensive …